Search research articles
Contact Us
Filters
Showing results (221-230 of 255) with videos related to
Page
of 26
Sort By:
Schizophrenia Research
|
August 15, 2021
Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders
Courtney L M Eskridge, William C Hochberger, Erin T Kaseda, et al.
The American Journal of Psychiatry
|
May 17, 2011
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD
Cheryl L P Vigen, Wendy J Mack, Richard S E Keefe, et al.
Psychopharmacology
|
July 18, 2014
Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia
Christine E Marx, Jimmy Lee, Mythily Subramaniam, et al.
The American Journal of Psychiatry
|
June 1, 2004
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol
Richard S E Keefe, Larry J Seidman, Bruce K Christensen, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
August 11, 2018
TOMMORROW neuropsychological battery: German language validation and normative study
Heather R Romero, Andreas U Monsch, Kathleen M Hayden, et al.
Schizophrenia Research
|
April 2, 2019
Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial
Henry W Mahncke, Sarah-Jane Kim, Annika Rose, et al.
The Journal of Clinical Psychiatry
|
September 7, 2010
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia
Stanley N Caroff, Vicki G Davis, Del D Miller, et al.
The American Journal of Psychiatry
|
May 28, 2025
Impact of Polygenic Interactions With Anticholinergic Burden on Cognition and Brain Structure in Psychosis Spectrum Disorders
Lusi Zhang, Elena I Ivleva, David A Parker, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
November 26, 2010
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia
Joseph L McClay, Daniel E Adkins, Karolina Aberg, et al.
Schizophrenia Research
|
April 10, 2017
Cognitive burden of anticholinergic medications in psychotic disorders
Seenae Eum, S Kristian Hill, Leah H Rubin, et al.
Page
of 26
Search research articles
Search
Showing results (221-230 of 255) with videos related to
Sort By:
Page
of 26
Schizophrenia Research
|
August 15, 2021
Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders
Courtney L M Eskridge, William C Hochberger, Erin T Kaseda, et al.
The American Journal of Psychiatry
|
May 17, 2011
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD
Cheryl L P Vigen, Wendy J Mack, Richard S E Keefe, et al.
Psychopharmacology
|
July 18, 2014
Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia
Christine E Marx, Jimmy Lee, Mythily Subramaniam, et al.
The American Journal of Psychiatry
|
June 1, 2004
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol
Richard S E Keefe, Larry J Seidman, Bruce K Christensen, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
August 11, 2018
TOMMORROW neuropsychological battery: German language validation and normative study
Heather R Romero, Andreas U Monsch, Kathleen M Hayden, et al.
Schizophrenia Research
|
April 2, 2019
Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial
Henry W Mahncke, Sarah-Jane Kim, Annika Rose, et al.
The Journal of Clinical Psychiatry
|
September 7, 2010
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia
Stanley N Caroff, Vicki G Davis, Del D Miller, et al.
The American Journal of Psychiatry
|
May 28, 2025
Impact of Polygenic Interactions With Anticholinergic Burden on Cognition and Brain Structure in Psychosis Spectrum Disorders
Lusi Zhang, Elena I Ivleva, David A Parker, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
November 26, 2010
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia
Joseph L McClay, Daniel E Adkins, Karolina Aberg, et al.
Schizophrenia Research
|
April 10, 2017
Cognitive burden of anticholinergic medications in psychotic disorders
Seenae Eum, S Kristian Hill, Leah H Rubin, et al.
Page
of 26